BioCentury
ARTICLE | Clinical News

GLPG0974: Phase I data

April 1, 2013 7:00 AM UTC

A double-blind, placebo-controlled, Belgian Phase I trial in 32 healthy volunteers showed that once- and twice-daily ascending-doses of oral GLPG0974 for 2 weeks were well tolerated and dose-dependent...